Synthetic DNA: The New Standard in Scalable GMP-Grade Manufacture for mRNA Therapeutics
- Exploring opDNA®, an application-specific IVT template open at the 3’ end, facilitating direct use in the IVT reaction without enzymatic linearization. As a linear template without bacterial backbone sequences, equivalent mRNA yields are achieved with less DNA mass
- Homologous recombination of polyA tails in bacterial hosts is a major limitation of plasmid DNA. 4basebio’s enzymatic platform can handle long polyA tails (>180 bp) encoded directly into the template, while our novel polyA analytics ensure homogeneity in every construct
- Clinically validated and regulatory-ready, opDNA® supports efficient, flexible, and compliant manufacturing.
- This approach can support clinical programs at every scale, from large-scale production to small-batch and scale-out demands of personalized immunotherapies